Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.50 |
| ▸ | NPC1 | O15118 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | SCD | O00767 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2027017 | 1.00 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL3737773 | 0.92 | ALDH1A1 (0.48) | RAB9ANPC1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL1995415 | 0.92 | ALDH1A1 (0.48) | RAB9ANPC1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL265000 | 0.90 | SLC18A3 (0.51) | RAB9ANPC1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL15513886 | 0.86 | SLC18A3 (0.42) | RAB9ANPC1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL3184817 | 0.84 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL3183827 | 0.84 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL3183837 | 0.84 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL25322608 | 0.83 | MAPT (0.58) | RAB9ANPC1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL2937126 | 0.83 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2895477-B1 | PYRAZOLE CARBOXAMIDE DERIVATIVES AS TAAR MODULATORS FOR USE IN THE TREATMENT OF SEVERAL DISORDERS, SUCH AS DEPRESSION, DIABETES AND PARKINSON'S DISEASE. | HOFFMANN LA ROCHE (CH) | 2017-11-01 | — | — | EP | disclosed |
| US-9487501-B2 | Pyrazole carboxamide compounds and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20150218131-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| EP-2895477-A1 | PYRAZOLE CARBOXAMIDE DERIVATIVES AS TAAR MODULATORS FOR USE IN THE TREATMENT OF SEVERAL DISORDERS, SUCH AS DEPRESSION, DIABETES AND PARKINSON'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2015-07-22 | — | — | EP | disclosed |
| WO-2014041007-A1 | PYRAZOLE CARBOXAMIDE DERIVATIVES AS TAAR MODULATORS FOR USE IN THE TREATMENT OF SEVERAL DISORDERS, SUCH AS DEPRESSION, DIABETES AND PARKINSON'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218131-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | HCRTR1, TAAR1, HCRTR2 | RAB9A 2915/4885NPC1 996/4885SMN1; SMN2 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.